• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估替沙格赛定及其在复发或难治性弥漫性大B细胞淋巴瘤治疗中的潜力：迄今的证据。

Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.

作者信息

Zavras P D, Wang Y, Gandhi A, Lontos K, Delgoffe G M

机构信息

Infectious Disease Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Tumor Microenvironment Center, UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA, USA.

出版信息

Onco Targets Ther. 2019 Jun 11;12:4543-4554. doi: 10.2147/OTT.S177844. eCollection 2019.

DOI:10.2147/OTT.S177844
PMID:31354288
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6572744/
Abstract

Chimeric antigen receptor (CAR) T cells have changed the treatment landscape of relapsed or refractory diffuse large B cell lymphoma. This review focuses on the biology of tisagenlecleucel and the clinical data that support its use in this setting. In addition, we discuss how it compares to other CAR T products, the financial implications for payers, and ongoing trials.

摘要

嵌合抗原受体（CAR）T细胞已经改变了复发或难治性弥漫性大B细胞淋巴瘤的治疗格局。本综述重点关注替沙格韦单抗的生物学特性以及支持其在这种情况下使用的临床数据。此外，我们还讨论了它与其他CAR T产品的比较、对支付方的财务影响以及正在进行的试验。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398a/6572744/2a7ca14b3511/OTT-12-4543-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398a/6572744/2a7ca14b3511/OTT-12-4543-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/398a/6572744/2a7ca14b3511/OTT-12-4543-g0001.jpg

相似文献

1
Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date.评估替沙格赛定及其在复发或难治性弥漫性大B细胞淋巴瘤治疗中的潜力：迄今的证据。
Onco Targets Ther. 2019 Jun 11;12:4543-4554. doi: 10.2147/OTT.S177844. eCollection 2019.
2
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
3
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma.tisagenlecleucel 在复发/难治性急性淋巴细胞白血病和弥漫性大 B 细胞淋巴瘤中的免疫原性。
Blood Adv. 2021 Dec 14;5(23):4980-4991. doi: 10.1182/bloodadvances.2020003844.
4
CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products.用于B细胞淋巴瘤的嵌合抗原受体T细胞疗法：现有产品的临床试验结果
Ther Adv Hematol. 2019 Apr 15;10:2040620719841581. doi: 10.1177/2040620719841581. eCollection 2019.
5
Economic Burden of Neurologic Toxicities Associated with Treatment of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.美国复发或难治性弥漫性大B细胞淋巴瘤患者治疗相关神经毒性的经济负担
Am Health Drug Benefits. 2020 Oct-Nov;13(5):192-199.
6
Chimeric Antigen Receptor-Engineered T-Cells - A New Way and Era for Lymphoma Treatment.嵌合抗原受体修饰 T 细胞 - 淋巴瘤治疗的新方法和新纪元。
Recent Pat Anticancer Drug Discov. 2019;14(4):312-323. doi: 10.2174/1574892814666191022164641.
7
Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy.行业向细胞疗法的巨大飞跃：推动嵌合抗原受体 T 细胞（CAR-T）免疫疗法。
Curr Hematol Malig Rep. 2019 Feb;14(1):47-55. doi: 10.1007/s11899-019-0498-6.
8
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials.在关键临床试验期间优化嵌合抗原受体T细胞（CAR-T）制造工艺
Mol Ther Methods Clin Dev. 2019 Nov 29;16:136-144. doi: 10.1016/j.omtm.2019.11.018. eCollection 2020 Mar 13.
9
Prolonged Responses in Central Nervous System Relapsed Diffuse Large B-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy Using Targeted Treatments.使用靶向治疗的嵌合抗原受体T细胞疗法后中枢神经系统复发的弥漫性大B细胞淋巴瘤的长期反应
Cureus. 2024 Aug 6;16(8):e66291. doi: 10.7759/cureus.66291. eCollection 2024 Aug.
10
Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia.替沙格韦单抗治疗弥漫性大B细胞淋巴瘤和B系急性淋巴细胞白血病患者后的长期宿主免疫调节
Cancers (Basel). 2023 Apr 22;15(9):2411. doi: 10.3390/cancers15092411.

引用本文的文献

1
Immunotherapies for pediatric cancer: current landscape and future perspectives.儿童癌症的免疫疗法：现状与未来展望。
Cancer Metastasis Rev. 2019 Dec;38(4):573-594. doi: 10.1007/s10555-019-09819-z.

本文引用的文献

1
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.ASTCT 细胞因子释放综合征和免疫效应细胞相关神经系统毒性的共识分级标准。
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25.
2
Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group.苯达莫司汀作为侵袭性淋巴瘤患者自体干细胞移植预处理方案的一部分：GELTAMO 研究组的一项 2 期研究。
Br J Haematol. 2019 Mar;184(5):797-807. doi: 10.1111/bjh.15713. Epub 2018 Dec 12.
3
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.
阿基仑赛注射液治疗难治性大 B 细胞淋巴瘤的长期安全性和疗效（ZUMA-1）：一项单臂、多中心、1-2 期临床试验。
Lancet Oncol. 2019 Jan;20(1):31-42. doi: 10.1016/S1470-2045(18)30864-7. Epub 2018 Dec 2.
4
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
5
Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma.抗CD19嵌合抗原受体T细胞疗法：利用免疫系统的力量对抗弥漫性大B细胞淋巴瘤。
Curr Hematol Malig Rep. 2018 Dec;13(6):534-542. doi: 10.1007/s11899-018-0482-6.
6
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.嵌合抗原受体 T 细胞疗法治疗复发或难治性儿童白血病患者的长期生存和价值。
JAMA Pediatr. 2018 Dec 1;172(12):1161-1168. doi: 10.1001/jamapediatrics.2018.2530.
7
Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.嵌合抗原受体T细胞疗法在复发或难治性儿童B细胞急性淋巴细胞白血病中的成本效益
J Clin Oncol. 2018 Nov 10;36(32):3192-3202. doi: 10.1200/JCO.2018.79.0642. Epub 2018 Sep 13.
8
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.Tisagenlecleucel 治疗 B 细胞急性淋巴细胞白血病的临床药理学。
Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6.
9
Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function.嵌合抗原受体信号的磷酸化蛋白质组学分析揭示了影响细胞功能的动力学和定量差异。
Sci Signal. 2018 Aug 21;11(544):eaat6753. doi: 10.1126/scisignal.aat6753.
10
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.